Literature DB >> 32861152

Status epilepticus and other EEG findings in patients with COVID-19: A case series.

Wendy Chen1, Sheela Toprani2, Katherine Werbaneth2, Jessica Falco-Walter2.   

Abstract

PURPOSE: Neurological manifestations of COVID-19 infection include impaired consciousness, strokes, and seizures. Limited reports describing EEG abnormalities in patients with COVID-19 have been published. These articles reported nonspecific encephalopathic patterns, epileptiform discharges, and rarely seizures. Our primary aim was to assess EEG abnormalities in patients with COVID-19 and evaluate for epileptiform activity or seizures.
METHODS: We identified five critically ill adult patients with COVID-19 who underwent EEG monitoring. All patients had Ceribell™ rapid response EEG initially and two continued with conventional long-term video EEG.
RESULTS: All 5 patients had encephalopathy and 3 also had seizure-like movements, thus prompting EEG monitoring. EEGs all showed nonspecific markers of encephalopathy including diffuse slowing and generalized rhythmic delta activity. Two also had epileptiform discharges reaching 2-3 Hz at times, with one patient in nonconvulsive status epilepticus and the other developing clinical status epilepticus with myoclonic movements. EEG and clinical symptoms improved with anti-seizure medications.
CONCLUSION: Status epilepticus was present in 2 out of our cohort of 5 critically ill patients who underwent EEG monitoring. These findings highlight the importance of EEG monitoring in high-risk patients with COVID-19 and encephalopathy. EEG recordings in such patients can identify pathological patterns that will benefit from treatment with anti-seizure medications.
Copyright © 2020 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Case series; EEG; Encephalopathy; Seizures

Mesh:

Year:  2020        PMID: 32861152      PMCID: PMC7441944          DOI: 10.1016/j.seizure.2020.08.022

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


Introduction

COVID-19, an acronym for “coronavirus disease of 2019,” is a disease caused by the pathogen “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) [1]. This illness can have neurologic manifestations including stroke, impaired consciousness, skeletal muscle injury, anosmia or dysgeusia, headache, dizziness, and seizures [2]. Patients with COVID-19 infection can have clinical seizures and nonconvulsive seizures without overt motor symptoms causing altered mentation. Due to the risk of exposure to electroencephalography (EEG) technicians, conventional EEG monitoring is typically reserved for situations where the suspicion for seizures is high. An alternative is Ceribell™ rapid response EEG (rapid-EEG) (Ceribell Inc., Mountain View, CA, USA), which can be quickly applied by healthcare personnel without prior EEG technology training. Its use enables screening for seizures in high-risk patients [3] and reduces the risk of exposure to healthcare personnel. Data on EEG findings of patients with COVID-19 still remain scarce. In a recent case series, epileptiform discharges were seen in 40.9% of COVID-19 positive patients with frontal sharp waves as the predominant pattern [4]. Several other case studies showed that patients can have diffuse slowing, bifrontal discharges, or generalized periodic discharges [5,6]. There were rare reports of status epilepticus confirmed on EEG recordings [[7], [8], [9], [10], [11]]. In our case series, we report the findings of five critically ill patients with COVID-19 infection who underwent EEG monitoring.

Methods

In this retrospective case series, we identified 5 adult patients admitted either at Stanford Hospital or Stanford ValleyCare Hospital between June 1st and July 4th, 2020 who were critically ill from COVID-19 infection and underwent EEG monitoring. Informed consent was obtained from the patients’ family. They were all in the intensive care unit (ICU), requiring intubation and compassionate use remdesivir. The patients were diagnosed with COVID‐19 by SARS-CoV-2 RNA detection from nasopharyngeal swab testing using FDA-approved assays. They all had nonlesional head computed tomography (CT) except for one patient. EEGs were typically ordered for mental status changes or seizure-like activity. All patients had rapid-EEG initially and two subsequently transitioned to conventional long-term video EEG monitoring. Rapid-EEG recordings used a 10-electrode (8-channel) system, consisting of Fp1, Fp2, F7, F8, T3, T4, T5, T6, O1, and O2, and read in a reduced double banana montage. Sampling rate was 250 Hz and high and low pass filters were 1 Hz and 70 Hz respectively. Conventional continuous video EEG was acquired with a digital EEG machine (Neurofax EEG-1200, Nihon Kohden Co., Tokyo, Japan) and included 24 channels with the international 10–20 system for electrode placements and an EKG lead. Sampling rate was 500 Hz, with a time constant of 0.1 s (high pass filter of ∼1.59 Hz) and low pass filter of 70 Hz. The gain was set at 50 μV for rapid-EEG and 7 μV for conventional EEG, with a notch filter of 60 Hz. Rapid-EEG was placed by nursing staff and conventional EEG was applied by EEG technicians. All EEG recordings were reviewed by an epilepsy fellow and a supervising board-certified epileptologist.

Results

Patient 1

A 37-year-old female with multiple comorbidities including end-stage renal disease on dialysis presented with 1 week of diarrhea. Initial COVID-19 testing was negative but repeat testing one day later was positive. She was intubated and sedated on midazolam infusion. Two days later, she had increased oxygen requirements, worsening mental status, and full body jerking movements. Rapid-EEG showed continuous spike and slow wave discharges that appeared bifrontal predominant at up to 3 Hz associated with myoclonic movements, consistent with status epilepticus (Fig. 1 A-a). She was loaded with levetiracetam and later phenytoin and started on maintenance levetiracetam and phenytoin. Her myoclonic movements resolved and her EEG concurrently showed less frequent discharges. Given ongoing encephalopathy, she had two lumbar punctures (LP) performed which were unremarkable. She later also had conventional continuous EEG, which showed diffuse slowing with intermittent generalized rhythmic delta activity (GRDA) and occasional generalized periodic discharges (GPDs) at 0.5−1 Hz (Fig. 1A-b). Discharges slowly improved the course of the recordings, as well as her mental status.
Fig. 1

EEG recordings in the 5 patients with COVID-19 infection viewed in 10 s epochs. Rapid-EEG recordings are in a limited double banana montage viewed at a sensitivity of 50 μV, with the top 4 channels representing the left hemisphere and the bottom 4 channels representing the right hemisphere. Conventional EEG recordings are in double banana montage viewed at a sensitivity of 7 μV.

(A) a. Initial rapid-EEG on the first patient showing 2−3 Hz bifrontal predominant spike and wave discharges.

b. Conventional EEG showing improvement after starting on anti-seizure medications, with generalized rhythmic delta activity (GRDA) and occasional generalized periodic discharges (GPDs) at mostly 0.5−1 Hz.

(B) Rapid-EEG on the second patient showing GPDs reaching 2−3 Hz at times.

(C) Rapid-EEG on the third patient showing moderate-severe diffuse slowing and GRDA.

(D) a. Initial rapid-EEG on the fourth patient showing severe diffuse slowing.

b. Conventional EEG performed later showing moderate-severe diffuse slowing and GRDA.

(E) Rapid-EEG on the fifth patient showing moderate diffuse slowing and GRDA.

EEG recordings in the 5 patients with COVID-19 infection viewed in 10 s epochs. Rapid-EEG recordings are in a limited double banana montage viewed at a sensitivity of 50 μV, with the top 4 channels representing the left hemisphere and the bottom 4 channels representing the right hemisphere. Conventional EEG recordings are in double banana montage viewed at a sensitivity of 7 μV. (A) a. Initial rapid-EEG on the first patient showing 2−3 Hz bifrontal predominant spike and wave discharges. b. Conventional EEG showing improvement after starting on anti-seizure medications, with generalized rhythmic delta activity (GRDA) and occasional generalized periodic discharges (GPDs) at mostly 0.5−1 Hz. (B) Rapid-EEG on the second patient showing GPDs reaching 2−3 Hz at times. (C) Rapid-EEG on the third patient showing moderate-severe diffuse slowing and GRDA. (D) a. Initial rapid-EEG on the fourth patient showing severe diffuse slowing. b. Conventional EEG performed later showing moderate-severe diffuse slowing and GRDA. (E) Rapid-EEG on the fifth patient showing moderate diffuse slowing and GRDA.

Patient 2

A 60-year-old female with hypertension presented with progressive shortness of breath, myalgias, diarrhea, and chest and abdominal pain for 1 week. She was found to have COVID-19 and subsequently intubated and sedated with midazolam. Rapid-EEG was ordered for encephalopathy, which showed abundant 1 Hz GPDs with occasional bursts at 2−3 Hz (Fig. 1B), concerning for nonconvulsive status epilepticus. Around the time of the EEG recording, she also had hypernatremia, a left peroneal deep vein thrombosis, bleeding from a chest wall hematoma, and left apical pneumothorax. An LP was not performed for encephalopathy. She was started on levetiracetam with improvement in her discharges and mentation and later recordings showing moderate diffuse slowing and GRDA.

Patient 3

A 50-year-old male without significant medical history was brought in for 1 day of shortness of breath and myalgias and found to be COVID-19 positive. He also had an episode of whole body shaking prior to arrival. He was intubated and sedated on propofol. LP performed was unremarkable. He was loaded with levetiracetam and started on maintenance therapy. Rapid-EEG was placed and showed moderate to severe diffuse slowing and intermittent GRDA (Fig. 1C).

Patient 4

A 38-year-old female with complex comorbidities including orthotopic heart transplant and heterotopic kidney transplant, pulmonary hypertension, diabetes, and chronic congestive hepatopathy was brought in after being found down by family with seizure-like movements. Initial COVID-19 testing in the emergency room was negative but was later positive when retested a few days later due to worsening encephalopathy and fevers. She was intubated and sedated on propofol. Patient was connected to rapid-EEG and started on levetiracetam. EEG showed mostly severe diffuse slowing with a low amplitude background (Fig. 1D-a). There were no epileptiform discharges or seizures. Due to ongoing encephalopathy and the desire for prolonged EEG recording, rapid-EEG was converted to conventional EEG, which showed moderate-severe diffuse slowing with intermittent GRDA (Fig. 1D-b). She also had an LP, which was unremarkable.

Patient 5

A 40-year-old male with atrial fibrillation, hypertension, and diabetes with multiple vascular complications including chronic kidney disease presented with fevers, generalized weakness, nausea, and vomiting. He was found to have COVID-19 infection and in hypoxic respiratory failure. He was subsequently intubated and sedated on dexmedetomidine. LP was unremarkable. CT head showed multifocal hypodensities, which were suspected to be small subacute-chronic strokes due to atrial fibrillation. These lesions would not explain his acute encephalopathy, so he received rapid-EEG which showed moderate diffuse slowing and GRDA (Fig. 1E).

Discussion

We describe five critically ill patients with COVID-19 who underwent EEG monitoring due to altered mentation or seizure-like movements. The EEGs in all the patients showed some degree of diffuse slowing and GRDA, both nonspecific markers of encephalopathy. Two patients also had epileptiform discharges that reached >2.5 Hz, meeting criteria for status epilepticus [12]. One patient had myoclonic movements correlating with the discharges. The discharges improved in both patients with the administration of anti-seizure medications; the patient with myoclonic activity also had resolution of her movements. Like prior reports, this case series demonstrates that EEG abnormalities in COVID-19 positive patients consist of nonspecific indicators of encephalopathy and epileptiform activity including bifrontal predominant and generalized discharges. However, a limited montage EEG was used in most patients and might not be able to detect focal findings in the parasagittal region. In our cohort, we also found that 2 out of 5 patients had ictal patterns on their EEGs meeting criteria for status epilepticus initially. These patterns and their clinical symptoms subsequently improved with anti-seizure medications. This case series demonstrates that there is potentially a pathogenic role of COVID-19 infection in triggering de novo seizures and status epilepticus in patients, highlighting the importance of EEG monitoring in patients with altered mentation or seizure-like activity. EEG recordings in such patients can identify pathological patterns that will benefit from treatment with anti-seizure medications. However, the patients in our cohort were all critically ill and most had underlying chronic medical problems including chronic kidney disease, making them more susceptible to nonspecific EEG abnormalities as well as status epilepticus. Patient 2 also had multiple complications during her ICU stay, further increasing her risk of seizures. The clinical benefit and risk of exposure from EEG evaluation need to be considered. Rapid-EEG may be a more efficient way of screening patients for seizures and status epilepticus and limit the risk of exposure. Further studies elucidating the epileptogenesis of COVID-19 infection are needed.

Funding

This paper did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The authors report no declarations of interest.
  9 in total

1.  Status epilepticus due to COVID-19; a cases series and literature review.

Authors:  Mohsen Kheradmand; Helia Hemasian; Fariborz Khorvash; Mohammad Reza Najafi; Keyvan Ghadimi; Khatereh Forouharnejad; Mohammad Amin Najafi
Journal:  Am J Neurodegener Dis       Date:  2022-06-20

2.  Seizures and COVID-19: Results from the Spanish Society of Neurology's COVID-19 registry.

Authors:  Santiago Fernández Fernández; Javier Ricardo Pérez Sánchez; Guillermo Hernández Pérez; María Rabasa Pérez; Cristina Guijarro Castro; David García-Azorín; David Ezpeleta
Journal:  J Clin Neurosci       Date:  2022-05-16       Impact factor: 2.116

Review 3.  Status epilepticus and COVID-19: A systematic review.

Authors:  Fedele Dono; Bruna Nucera; Jacopo Lanzone; Giacomo Evangelista; Fabrizio Rinaldi; Rino Speranza; Serena Troisi; Lorenzo Tinti; Mirella Russo; Martina Di Pietro; Marco Onofrj; Laura Bonanni; Giovanni Assenza; Catello Vollono; Francesca Anzellotti; Francesco Brigo
Journal:  Epilepsy Behav       Date:  2021-03-17       Impact factor: 3.337

4.  High Incidence of Epileptiform Potentials During Continuous EEG Monitoring in Critically Ill COVID-19 Patients.

Authors:  Barbara Schultz; Terence Krauß; Maren Schmidt; Michael Schultz; Andrea Schneider; Olaf Wiesner; Julius J Schmidt; Klaus Stahl; Sascha David; Marius M Hoeper; Markus Busch
Journal:  Front Med (Lausanne)       Date:  2021-03-26

5.  Recurrent Status Epilepticus and SARS-CoV-2 infection: the "perfect storm".

Authors:  Giada Pauletto; Annacarmen Nilo; Cristian Deana; Lorenzo Verriello; Ilaria Del Negro; Christian Lettieri; Luigi Vetrugno; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Acta Biomed       Date:  2021-11-03

6.  New-Onset Non-convulsive Status Epilepticus in Previously Healthy COVID-19 Patient.

Authors:  Ika Noviawaty
Journal:  Cureus       Date:  2022-08-22

7.  The value of EEG attenuation in the prediction of outcome in COVID-19 patients.

Authors:  Lucio Marinelli; Irene Pappalardo; Chiara Robba; Laura Saitta; Corrado Cabona; Denise Battaglini; Monia Casaleggio; Anna Bellini; Alessandra Ferrari; Iole Brunetti; Flavio Villani
Journal:  Neurol Sci       Date:  2022-08-27       Impact factor: 3.830

Review 8.  COVID-19-Induced Seizures: A Meta-Analysis of Case Series and Retrospective Cohorts.

Authors:  Helai Hussaini; Sylvette Rogers; Saurabh Kataria; Khalid Uddin; Khalid H Mohamed; Alaa S Mohamed; Farhan Tariq; Sarfaraz Ahmad; Anum Awais; Zahoor Ahmed; Anthony Chukwurah; Aadil Khan
Journal:  Cureus       Date:  2022-08-31

Review 9.  Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients.

Authors:  Steven T DeKosky; Patrick M Kochanek; Alex B Valadka; Robert S B Clark; Sherry H-Y Chou; Alicia K Au; Christopher Horvat; Ruchira M Jha; Rebekah Mannix; Stephen R Wisniewski; Max Wintermark; Susan E Rowell; Robert D Welch; Lawrence Lewis; Stacey House; Rudolph E Tanzi; Darci R Smith; Amy Y Vittor; Nancy D Denslow; Michael D Davis; Olena Y Glushakova; Ronald L Hayes
Journal:  J Neurotrauma       Date:  2020-11-11       Impact factor: 5.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.